This invention also relates to complexes formed between lymphotoxin-β and other peptides such as lymphotoxin-α and to complexes comprising multiple subunits of lymphotoxin-β.
The disclosure further relates to the lymphotoxin pathway.
This invention relates to lymphotoxin-β, a lymphocyte membrane type protein.
Compositions comprising lymphotoxin pathway inhibitors are described.
This invention relates to a membrane associated protein, p33, and the complex it forms with a soluble lymphotoxin.
LT can be employed, for instance, with chemotherapy or radiation therapy to provide improved anti-cancer therapy.
Methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties.
Therapeutic uses of inhibitors of the Lymphotoxin Pathway to treat tumors, specifically to treat follicular lymphomas.
Methods and compositions are provided which include use of lymphotoxin ('LT') and one or more other anti-cancer therapies for treating cancer in vivo or ex vivo.
The present invention relates to a soluble lymphotoxin (solLT) and methods of using the solLT as a biomarker in the treatment of autoimmune disease.
Methods and compositions are provided which include use of lymphotoxing ('LT') and one or more other anti-cancer therapies for treating cancer in vivo or ex vivo.
A tumor necrosis factor and lymphotoxin homolog having apoptotic activity, identified as Apo-3 Ligand, is provided.
The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LTβR) modulators, which activate or inhibit LTβR signaling.
More particularly, the present invention relates to soluble lymphotoxin alpha-beta (solLTαβ) and methods of using this solLTαβ as a biomarker in the treatment of rheumatoid arthritis (RA).
Infliximab does not neutralize TNFβ (lymphotoxin-α), a related cytokine that utilizes the same receptors as TNFα.
An application set is disclosed for producing a two-component adhesive, useful for healing wounds, that contains TNF and/or LT.
This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other biologic agents, as well as therapeutic methods.
TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs.
Pennica D et. al. () Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.
In particular, cancer cells are recognized and destroyed by a number of cytokines, especially such as tumor necrosis factor and lymphotoxin.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод